Prevention

• flecainide ^a - at least 100 mg twice daily ^a  

Why?

• Flecainide reduces symptomatic arrhythmias better than placebo ^a .  In addition the interval between attacks is longer (on average 17 days longer). ^a
• Fewer patients on flecainide withdraw than do those on quinidine ^a

Paroxysmal or persistent AF: flecainide maintains sinus rhythm

Patient	Treatment	Comparison	Outcome	CER	OR (95% CI)	NNT (95% CI)
paroxysmal or persistent AF a	flecainide	control	sinus rhythm at months	30%	3.1 (1.5 to 6.2)	4 (2 to 11)

Paroxysmal AF: flecainide causes fewer side-effects than quinidine

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
symptomatic paroxysmal AF or flutter a	flecainide	quinidine	discontinued medication due to adverse effects at 12 months	30%	40% (4% to 62%)	8 (4 to 88)